| |
In This Issue - November 2008
Metabolic
Syndrome News
(from October 2008)
|
| Epidemiology |
Socioeconomic
differences in components of the metabolic syndrome
partly account for the social gradient in coronary
heart disease
(Posted: 10/29 | View
Article)
An overweight cohort in childhood
does not necessarily continue to be overweight
in young adulthood
(Posted: 10/22 | View
Article)
Metabolic syndrome shown to
be highly prevalent in the United Arab Emirates
(Posted: 10/20 | View
Article)
Relationship between the metabolic
syndrome and several sociodemographic factors
and C-reactive protein in the MADRIC (MADrid
RIesgo Cardiovascular) Study
(Posted: 10/17 | View
Article)
Metabolic syndrome and impaired
quality of life association in a population-based
study of Swedish women
(Posted: 10/15 | View
Article) |
|
Metabolic syndrome associated
with decreased prostate-specific antigen levels
(Posted: 10/10 | View
Article)
Metabolic syndrome associated
with lower mortality in heart failure patients
(Posted: 10/09 | View
Article)
Obesity, high triglycerides, high
insulin, high CRP, and family history of hypertension
and type 2 diabetes as childhood predictors of
adult metabolic syndrome
(Posted: 10/08 | View
Article)
Alanine aminotransferase shown
to be associated with all components of the metabolic
syndrome in Korean adults
(Posted: 10/06 | View
Article)
The obese without metabolic risk
factor clustering and the normal-weight with
metabolic risk factor clustering among the US
population
(Posted: 10/02 | View
Article) |
| |
Screening
/ Diagnosis
|
Fasting
or nonfasting status shown to alter associations
of lipids with
cardiovascular disease
(Posted: 10/24 | View
Article)
|
|
Significant
correlation between adiponectin and fasting indices
of insulin resistance in Greek children and adolescents
(Posted: 10/21 | View
Article)
|
| |
| Pathophysiological
Effects |
Metabolic syndrome associated
with higher prevalence of left ventricular
(LV) hypertrophy and left atrial dilation and
with a reduction of LV function in the young
(Posted: 10/30 | View
Article)
Associations of coronary heart disease risk
factors with arterial tissue lipids in young
subjects
(Posted: 10/28 | View
Article)
Metabolically unfavourable body composition
leading to increased risk of metabolic and
cardiovascular diseases in psychotic patients
(Posted: 10/23 | View
Article)
|
|
No association
found between genetic variants associated with
insulin resistance and metabolic syndrome in
young Asian Indians presenting with myocardial
infarction
(Posted: 10/16 | View
Article)
Independent association of insulin and 24-h
urinary noradrenaline with metabolic syndrome
(Posted: 10/13 | View
Article)
Resistin shown to be more strongly associated
with inflammatory and fibrinolytic markers
than with obesity and insulin resistance
(Posted: 10/07 | View
Article)
Metabolically benign obesity: its identification
and characterization
(Posted: 10/03 | View
Article)
|
| |
| Metabolic
Syndrome Components / Risk Factors / Associated
Risks |
ELEVATED
FASTING GLUCOSE
Walking activity independently
associated with lower levels of circulatory
pro-inflammatory markers
(Posted: 10/01 | View
Article)
|
|
ABDOMINAL
OBESITY
Markers of abdominal adiposity
significantly associated with risk of stroke
and transient ischaemic attacks
(Posted: 10/27 | View
Article)
Interleukin-1 polymorphisms
associated with central obesity and metabolic
syndrome in a coronary heart disease population
(Posted: 10/14 | View
Article) |
| |
| Prognosis
/ Outcomes |
CARDIOVASCULAR DISEASE
Small,
dense low-density lipoproteins as predictors
of cardiovascular risk beyond traditional risk
factors
(Posted: 10/31 | View
Article)
|
|
Landmark
Studies & Ongoing Trials |
| STRADIVARIUS |
Type: |
Ongoing
Trials With Lifestyle and Obesity Management
(Imaging Studies) |
Overview: |
Effect of rimonabant
on progression of atherosclerosis in patients with
abdominal obesity and coronary artery disease: the
STRADIVARIUS randomized controlled trial. |
Outcome: |
Progression of coronary atherosclerosis as assessed by intravascular ultrasound
(IVUS).
|
Total Enrollment: |
839 patients
with abdominal obesity associated with current smoking
and/or metabolic syndrome, and angiographic evidence of
coronary heart disease. |
Comparison: |
Rimonabant
20 mg/d vs placebo. |
Design: |
Randomized,
double-blind, placebo control, parallel assignment |
Abstract: |
View
Abstract
|
| AdRem |
Type:
|
Ongoing
Trials With Antihypertensive Agents |
Overview:
|
Rationale
and design of the AdRem study: evaluating the effects of
blood pressure lowering and intensive glucose control on
vascular retinal disorders in patients with type 2 diabetes
mellitus. |
Outcome:
|
Progression
of two or more steps in ETDRS (Early Treatment Diabetic
Retinopathy Study) classification. |
Number
of Participants:
|
1978 high
risk patients with type 2 diabetes, with no previous ophthalmologic
intervention procedure that might interfere with retinal
circulation, and no affection likely to alter quality of
retinal stereo photographs. |
Comparison:
|
Perindopril-indapamide
vs placebo; and intensive modified-release gliclazide-based
glucose control regimen (targeting an HbA!c of 6.5% or
lower) vs usual guidelines-based therapy. AdRem is a substudy
of ADVANCE (ADVANCE Retinal Measurements). |
Design:
|
Randomized,
double-blind, placebo control, factorial assignment |
Abstract:
|
View Abstract |
|
Featured
Upcoming Congresses
(2008-2009)
|
| 3rd
International Congress on Prediabetes and Metabolic
Syndrome |
Date: |
April
1-4, 2009 |
Location: |
Nice,
France |
Website: |
http://www2.kenes.com |
| |
| XV
International Symposium on Atherosclerosis |
Date: |
June 14-18,
2009 |
Location: |
Boston, MA,
USA |
Website: |
http://www.isa2009.org/ |
|
|
2008 Metabolic Syndrome Institute Awards
|
DEADLINE:
December 31, 2008
PURPOSE
To promote new talents and research themes in the field
of metabolic syndrome, the Metabolic Syndrome Institute
(MSI) intends to stimulate experimental and clinical
research in the field of metabolic syndrome by granting
three annual awards – The MSI Awards for Metabolic
Syndrome Research – to scientists or clinicians
who will have submitted the best scientific applications
according to the MSI Award Jury.
ELIGIBILITY
The MSI Awards will be granted to young scientists or
clinicians working in the field of metabolic syndrome,
insulin resistance, and/or related cardiovascular risk
assessment and prevention
AWARDS
For the year 2008, three successful applicants will
be granted US $10,000 each or the equivalent in euros.
|
Framingham
Risk Assessment Tool
Estimates 10-year risk of developing
hard CHD
> View
Tool
Procam Risk Calculator
Estimates your risk
of a heart attack (myocardial infarction) within the
next 10 years based upon data of the PROCAM Study
> View
Calculator
SCORE
(European High Risk Chart)
Estimates 10 year risk
of fatal CVD in high risk regions of Europe by gender, age, systolic
blood pressure, total cholesterol and smoking status.
> View
Chart
UKPDS Risk Engine
The UKPDS Risk
Engine is a type 2 diabetes specific risk calculator
based on 53,000 patients years of data from the UK Prospective
Diabetes Study, which also provides an approximate 'margin
of error' for each estimate.
> View
Risk Engine
|
Mission
of the Metabolic
Syndrome Institute |
Created
in 2003, the Metabolic Syndrome Institute is an independent
and not for profit association. Its members are international
experts in lipid metabolism, diabetes, heart disease,
endocrinology obesity, genetics, epidemiology, basic
research and health economics. Being the first association
totally devoted to the dissemination of knowledge about
the metabolic syndrome, the Metabolic Syndrome Institute
will provide an international multidisciplinary approach
to a worldwide public health problem.
|
| |
Contact
Metabolic Syndrome Institute
|
212,
avenue Paul Doumer
92500 Rueil-Malmaison Cedex
FRANCE
Phone: (33) 1 41 42 20 35
Fax: (33) 1 41 42 20 01
Email:
contact@metabolic-syndrome-institute.org
Website:
http://www.metabolic-
syndrome-institute.org |
|
